Collectively, our data suggest that the pan-PI3K inhibitor PQR309, whether used as monotherapy or in combination with gemcitabine, can optimize anti-tumor efficacy without leading to increased in vivo toxicity when compared to the isoform-specific PI3K inhibitor BYL719. This evidence concerns the gene PIK3CA and neoplasm.